- Home
- REE vs ENTX Comparison
REE vs ENTX Comparison
Compare REE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- ENTX
- Stock Information
- Founded
- REE 2011
- ENTX 2010
- Country
- REE Israel
- ENTX Israel
- Employees
- REE N/A
- ENTX N/A
- Industry
- REE Auto Manufacturing
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REE Consumer Discretionary
- ENTX Health Care
- Exchange
- REE Nasdaq
- ENTX Nasdaq
- Market Cap
- REE 67.1M
- ENTX 69.6M
- IPO Year
- REE N/A
- ENTX 2018
- Fundamental
- Price
- REE $2.51
- ENTX $1.79
- Analyst Decision
- REE Strong Buy
- ENTX Strong Buy
- Analyst Count
- REE 3
- ENTX 1
- Target Price
- REE $12.50
- ENTX $10.00
- AVG Volume (30 Days)
- REE 221.0K
- ENTX 30.9K
- Earning Date
- REE 05-29-2025
- ENTX 05-09-2025
- Dividend Yield
- REE N/A
- ENTX N/A
- EPS Growth
- REE N/A
- ENTX N/A
- EPS
- REE N/A
- ENTX N/A
- Revenue
- REE $626,000.00
- ENTX $181,000.00
- Revenue This Year
- REE N/A
- ENTX N/A
- Revenue Next Year
- REE $21,152.58
- ENTX N/A
- P/E Ratio
- REE N/A
- ENTX N/A
- Revenue Growth
- REE N/A
- ENTX N/A
- 52 Week Low
- REE $2.35
- ENTX $1.41
- 52 Week High
- REE $11.72
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- REE 28.92
- ENTX 49.59
- Support Level
- REE $2.31
- ENTX $1.50
- Resistance Level
- REE $2.90
- ENTX $1.84
- Average True Range (ATR)
- REE 0.33
- ENTX 0.11
- MACD
- REE 0.13
- ENTX 0.03
- Stochastic Oscillator
- REE 23.28
- ENTX 85.50
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.